Introduction {#s01}
============

Innate immune recognition of invading pathogens by pattern-recognition receptors (PRRs) is important to initiate protective immune responses ([@bib25]; [@bib17]). Yet uncontrolled activation of PRRs by pathogen-associated molecular patterns (PAMPs), such as LPS, can result in unbalanced cytokine production and potentially fatal tissue injury. Neutrophils express multiple PRRs, including the LPS receptor TLR4 ([@bib13]), and are typically the first immune cells to be recruited to sites of infection ([@bib21]; [@bib26]; [@bib24]; [@bib27]). Neutrophils can efficiently kill bacteria through different defense mechanisms ([@bib3]; [@bib21]; [@bib26]; [@bib24]); however, some neutrophil products may be detrimental to the host, particularly in the context of excessive activation by PAMPs, such as during LPS-induced endotoxemia ([@bib26]; [@bib24]; [@bib27]). Indeed, it is generally considered that neutrophils exacerbate the inflammation and tissue damage associated with LPS exposure. Surprisingly, there is a lack of formal evidence to demonstrate this detrimental role for neutrophils. Moreover, systemic inflammation leads to a functionally heterogeneous neutrophil compartment ([@bib31]) and, in humans, low-dose LPS exposure induces the appearance of a subset of CD62L^dim^CD11b^high^ neutrophils that can suppress T cell activation ex vivo ([@bib32]). The latter finding suggests that some neutrophils might possess immunosuppressive functions in the context of endotoxemia.

In the present study, we used mouse models to investigate further the role of neutrophils during LPS-induced endotoxemia. There is a paucity of suitable models available to study neutrophil functions in vivo: animals with constitutive neutropenia exhibit other immune abnormalities and are more susceptible to infections ([@bib14]), whereas antibodies used at high doses to deplete neutrophils have known or likely effects on other cell populations ([@bib5]; [@bib6]). Therefore, we have developed a new mouse model, which we call *PMN^DTR^* mice, that allows selective and inducible ablation of neutrophils upon injection of diphtheria toxin (DT). Using this model, we discovered that, instead of exacerbating LPS-induced toxicity, neutrophils diminish the toxic effects and mortality induced by LPS in mice. We further demonstrated that this protective function is mediated by the major enzyme of neutrophils, myeloperoxidase (MPO).

Results and discussion {#s02}
======================

Antibody-mediated neutrophil depletion increases LPS-induced mortality {#s03}
----------------------------------------------------------------------

To evaluate the contribution of neutrophils to LPS-induced endotoxemia in mice, we first assessed the phenotype of mouse neutrophil activation after i.p. LPS administration. A marked dose-dependent decrease in expression of CD62L and increase in CD11b was observed in neutrophils from the blood ([Fig. 1, A--C](#fig1){ref-type="fig"}), peritoneal cavity, and BM (Fig. S1, A--D). This activated phenotype is consistent with the CD62L^dim^CD11b^high^ subset of blood neutrophils observed after injection of low-dose LPS in humans, which display immunosuppressive characteristics ex vivo ([@bib32]). We then assessed the role of neutrophils in the LPS-induced endotoxemia model using neutrophil-depleting antibodies. Neutrophil depletion by treatment with anti--Gr-1 or anti-Ly6G antibodies greatly increased the hypothermia and mortality induced by LPS injection ([Fig. 1, D--G](#fig1){ref-type="fig"}). Despite the development of considerable neutrophilia in mice treated with isotype control antibodies, mice treated with neutrophil-depleting antibodies remained neutropenic after LPS injection (Fig. S1, E and F).

![**Antibody-mediated neutrophil depletion results in increased mortality after LPS injection.** (A--C) Representative flow cytometry profile (A) and quantification of CD62L (B) and CD11b (C) by geometric mean fluorescence intensity (GeoMean) on Ly6G^+^ CD11b^+^ blood neutrophils 6 h after LPS injection at the indicated concentrations. Red areas outlined in A provide a visual indication of CD62L and CD11b on the neutrophil population from the control 0 group. B and C show values from individual mice; bars indicate means ± SEM pooled from two independent experiments. \*\*, P \< 0.01; \*\*\*, P \< 0.001 versus control 0 group by two-tailed Mann--Whitney *U* test. (D--I) Changes in body temperature (Δ°C \[mean ± SEM\]) and survival (percentage of live animals) after LPS injection in C57BL/6J mice treated i.p. with anti-Ly6G (D and E), anti--Gr-1 (F--I) neutrophil-depleting antibodies, or respective isotype control antibodies. Data in D--G are pooled from three independent experiments performed at Stanford University (total *n* = 10--12/group). Data in H are pooled from three independent experiments performed in the Institut Pasteur conventional SPF animal facility (total *n* = 21--26/group). Data in I are pooled from two independent experiments performed in the Institut Pasteur GF animal facility (total *n* = 18/group). \*\*, P \< 0.01; \*\*\*, P \< 0.001 versus the corresponding isotype control group by Mantel--Cox log-rank test. Arrows in D--I indicate days of i.p. injection of the neutrophil-depleting or isotype control antibodies.](JEM_20161238_Fig1){#fig1}

We obtained very similar results at both Stanford University and Institut Pasteur ([Fig. 1](#fig1){ref-type="fig"}, F and G vs. H). However, WT mice maintained at Institut Pasteur were more susceptible to LPS toxicity than mice at Stanford University (not depicted). Such a difference in LPS reactivity could reflect differences in the microbiological environment. Given the known impact of commensal bacteria on neutrophil functions (Zhang et al., 2015), we therefore compared responses to LPS and the effect of neutrophil depletion between mice housed in a conventional animal facility (specific pathogen free \[SPF\]) and those housed in a germ-free (GF) facility. We observed greatly reduced LPS-induced mortality in GF mice ([Fig. 1, H and I](#fig1){ref-type="fig"}), as described previously ([@bib36]), yet depletion of neutrophils using an anti--Gr-1 antibody increased mortality in both SPF and GF mice, and responses of anti--Gr-1--treated SPF and GF mice were statistically indistinguishable ([Fig. 1, H and I](#fig1){ref-type="fig"}). Therefore, neutrophils appear to play a microorganism-independent role in limiting the extent of endotoxin-induced lethal shock.

Neutrophil-depleted mice were also more susceptible to endotoxemia at a 10-times-reduced dose of LPS (2.5 mg/kg; Fig. S1, G and I): this lower dose was fatal when administered to neutrophil-depleted mice, but not controls. On the other hand, when LPS (10 µg/kg) was given in the context of liver damage (by co-administration of the hepatotoxin [d]{.smallcaps}-galactosamine), we did not observe a difference in susceptibility of neutrophil-depleted mice compared with controls (Fig. S1, H and J). These findings indicate that neutrophil depletion renders mice more susceptible to both low- and high-dose systemic LPS administration. However, the apparent protective effect of neutrophils is not evident when LPS is given in a model of acute liver damage.

A new mouse model for selective and inducible ablation of neutrophils confirms that neutrophil depletion enhances susceptibility to endotoxemia and sepsis {#s04}
----------------------------------------------------------------------------------------------------------------------------------------------------------

Because the efficiency and selectivity of neutrophil-depleting antibodies is still a matter of debate ([@bib6]; [@bib39]; [@bib28]; [@bib42]), we generated a new transgenic mouse model allowing selective and inducible ablation of neutrophils. We used MRP8-Cre mice expressing Cre recombinase under the control of the neutrophil-associated human MRP8 promoter, with an IRES-GFP reporter ([@bib29]; [@bib9]; [@bib1]). First, we confirmed that GFP expression, as a marker of Cre activity, is restricted to neutrophils among major mature immune cell types in the blood, BM, spleen, and peritoneal lavage fluid ([Fig. 2 A](#fig2){ref-type="fig"} and Fig. S2 A). When crossed to ROSA-iEYFP^KI^ reporter mice, the MRP8 promoter was described to drive Cre-mediated deletion in 80--95% of neutrophils, with minor leakage (\<20%) into some monocyte/macrophage populations ([@bib2]), a finding we confirmed in the blood compartment (Fig. S2 B). We then crossed MRP8-Cre mice with ROSA-iDTR^KI^ mice, which bear a Cre-inducible simian DT receptor (DTR; [@bib4]), to generate mice with DTR expression restricted to neutrophils. A single injection of DT had no effect in control mice (MRP8-Cre^−^; ROSA-iDTR^KI^, named hereafter *PMN^WT^* mice) but markedly reduced neutrophil numbers in the blood, spleen, and BM of MRP8-Cre^+^; ROSA-iDTR^KI^ (named hereafter *PMN^DTR^*) mice at 24 h ([Fig. 2, B--D](#fig2){ref-type="fig"}; and Fig. S2 C). We found no significant effect of DT treatment on most of the other major immune cell types we assessed: B and T lymphocytes, platelets, eosinophils, basophils, dendritic cells, macrophages, and BM granulocyte-macrophage progenitors (GMPs; Fig. S2, E--H). Notably, however, we observed a significant reduction in the numbers of blood monocytes and the Ly6C^hi^ population of spleen monocytes in DT-treated *PMN^DTR^* mice (Fig. S2, E and F), which is in accord with the data from MRP8-Cre^+^; ROSA-iEYFP^KI^ mice, indicating that some Cre expression occurs in the monocyte compartment ([@bib2]; Fig. S2 B). Consistent with a lack of effect of DT on GMPs, the neutrophil depletion in *PMN^DTR^* mice was transient, and blood neutrophils started to reappear 2 d after DT injection (Fig. S2 D).

![**Injection of DT in *PMN^DTR^* mice induces marked depletion of neutrophils and enhances susceptibility to LPS-induced endotoxemia.** (A) GFP expression (mean fluorescence intensity \[MFI\]) among leukocytes in the blood, BM, spleen, and peritoneal lavage fluid of *MRP8-Cre/iresGFP^+^* mice and *MRP8-Cre/iresGFP^−^* littermate controls. Results in A are pooled from three independent experiments, each column representing data from one mouse. (B--D) Numbers of blood (B), spleen (C), and BM (D) neutrophils 24 h after i.p. injection of 500 ng DT into *PMN^DTR^* mice and *PMN^WT^* littermate control mice. Results in B--D show values from individual mice; bars indicate means ± SEM pooled from three (C and D; total *n* = 7--8/group) or four (B; total *n* = 15--16/group) independent experiments. (E and F) Changes in body temperature (Δ°C \[mean ± SEM\]; E) and survival (percentage of live animals; F) after LPS injection in DT-treated *PMN^DTR^* and *PMN^WT^* mice. Data in E and F are pooled from three independent experiments (total *n* = 11/group); arrows indicate days of i.p. injection of DT. (G) Percentage of blood neutrophils before (time 0) and 3, 6, and 20 h after LPS injection in DT-treated *PMN^DTR^* mice and *PMN^WT^* controls. Data show values from individual mice; bars indicate means ± SEM pooled from three independent experiments (*n* = 6--10/group). (H--L) Levels of TNF-α (H), IL-6 (I), IL-10 (J), IFN-γ (K), and MCP-1 (L) in the plasma of DT-treated *PMN^DTR^* mice and *PMN^WT^* littermate controls before (time 0) and 6 h after LPS injection (*n* = 6--16/group). Results in H--L are means ± SEM pooled from three independent experiments. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 versus *PMN^WT^* group and ^\#^, P \< 0.05; ^\#\#^, P \< 0.01; ^\#\#\#^, P \< 0.001 versus same group at time 0 by Mann--Whitney *U* test (B--D and G--L) or Mantel--Cox log-rank test (E and F).](JEM_20161238_Fig2){#fig2}

In accord with the results obtained with neutrophil-depleting antibodies ([Fig. 1](#fig1){ref-type="fig"}), we found that *PMN^DTR^* mice were much more susceptible than *PMN^WT^* mice to the development of hypothermia and death after LPS injection ([Fig. 2, E and F](#fig2){ref-type="fig"}). Despite considerable neutrophilia in *PMN^WT^* mice, *PMN^DTR^* mice remained deficient in neutrophils after LPS injection ([Fig. 2 G](#fig2){ref-type="fig"}). We found elevated levels of cytokines and chemokines in the blood 6 h after LPS injection in *PMN^DTR^* mice compared with *PMN^WT^* mice ([Fig. 2, H--L](#fig2){ref-type="fig"}), supporting a protective role for neutrophils in LPS-induced endotoxemia.

To validate *PMN^DTR^* mice as a model to study neutrophils in vivo in an inflammatory context, we also assessed responses in the cecal ligation and puncture (CLP) model of polymicrobial sepsis (Fig. S2, I--M). Although CLP induced strong neutrophilia in *PMN^WT^* mice, neutrophils remained barely detectable in the blood and peritoneal cavity of DT-treated *PMN^DTR^* mice (Fig. S2 L). Confirming the critical role of neutrophils in defense against bacteria, we found that DT-treated *PMN^DTR^* mice had diminished survival after CLP compared with DT-treated *PMN^WT^* mice (Fig. S2 I), with greater numbers of bacteria in the blood and peritoneal cavity (Fig. S2, J and K) and elevated levels of cytokines and chemokines in the blood, 18 h after CLP (Fig. S2 M). Thus, *PMN^DTR^* mice represent a valuable model for studying neutrophils during in vivo inflammation and confirm a protective role for neutrophils in LPS-induced endotoxemia and CLP-mediated polymicrobial sepsis.

MPO plays a beneficial role during sepsis and endotoxemia {#s05}
---------------------------------------------------------

MPO is the major enzyme produced by neutrophils and has an antibacterial function in sepsis ([@bib19]). A recent study indicated that diminished MPO expression might be a good predictor for identifying septic shock patients at high risk of death ([@bib7]). We therefore hypothesized that, in addition to its antimicrobial properties, MPO might contribute to the beneficial function of neutrophils during LPS-induced endotoxemia. We first confirmed that MPO-deficient mice have increased mortality, elevated levels of blood cytokines and chemokines, and higher bacterial burden in the CLP model ([@bib11]; Fig. S3, A--E). We then assessed responses of *Mpo^−/−^* mice in the LPS-induced endotoxemia model. Circulating neutrophils from MPO-deficient animals acquired a CD62L^dim^CD11b^high^ phenotype similar to that of MPO-sufficient animals 6 h after injection of LPS ([Fig. 3 A](#fig3){ref-type="fig"} and Fig. S3 F). However, *Mpo^−/−^* mice developed significantly increased hypothermia and mortality in response to LPS compared with WT mice ([Fig. 3, B and C](#fig3){ref-type="fig"}), as well as elevated blood levels of cytokines and chemokines, despite similar levels of neutrophils in the blood (Fig. S3, G and H). Furthermore, treatment of WT mice with the MPO inhibitor 4-aminobenzoic acid hydrazide (4-ABAH; [@bib18]; [@bib12]; Zhang et al., 2013) significantly increased mortality in response to LPS, supporting a protective role for MPO during endotoxemia ([Fig. 3 D](#fig3){ref-type="fig"}).

![**Neutrophil-derived MPO diminishes LPS-induced hypothermia and mortality.** (A) Representative flow cytometry profile of Ly6G^+^ CD11b^+^ blood neutrophils 0 or 6 h after LPS injection in WT or *Mpo^−/−^* mice. Areas outlined in red indicate values for neutrophils from the control (time 0) group; data are representative of results obtained in two independent experiments. (B and C) Changes in body temperature (Δ°C \[mean ± SEM\]; B) and survival (percentage of live animals; C) after LPS injection in WT and *Mpo^−/−^* mice. (D) Survival after LPS injection in WT mice treated with the MPO inhibitor 4-ABAH or vehicle. Data in B--D are pooled from three independent experiments (total *n* = 11--13/group). \*\*, P \< 0.01; \*\*\*, P \< 0.001 versus respective WT group (C) or vehicle-treated group (D) by Mantel--Cox log-rank test. (E) MPO in the peritoneal lavage fluid 6 h after injection with PBS (*n* = 4) or LPS (*n* = 7/group). Values from individual mice are shown; bars indicate means ± SEM pooled from two independent experiments. \*\*, P \< 0.01; \*\*\*, P \< 0.001 versus PBS group and ^\#\#\#^, P \< 0.001 versus LPS-treated control group by unpaired Student's *t* test. (F--I) Bioluminescent visualization of MPO activity in various organs 6 h after injection of PBS or LPS in the indicated group. (F--H) Quantification of bioluminescence in spleen (F), liver (G), and lung (H). Data in F--H are means + SEM from three independent experiments (total *n* = 6--14/group) except for *Mpo^−/−^* mice (two independent experiments with a total of three to four mice). \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 versus PBS-treated WT group and ^\#^, P \< 0.05; ^\#\#^, P \< 0.01; ^\#\#\#^, P \< 0.001 versus corresponding LPS-treated control group by unpaired Student's *t* test. NS, not significant (P \> 0.05). (I) Representative images of different organs (Sp, spleen; L, liver; St, stomach; C, cecum; Du, duodenum; Ki, kidney; H, heart; and L, lung). (J and K) Changes in body temperature (J) and survival (K) after LPS injection in DT-treated *PMN^DTR^* mice (*n* = 9), *PMN^WT^* littermate controls (*n* = 24), and *PMN^DTR^* mice engrafted i.v. with 10^7^ purified BM neutrophils from WT mice (WT PMNs → *PMN^DTR^*; *n* = 16) or from *Mpo^−/−^* mice (*Mpo^−/−^* PMNs → *PMN^DTR^*; *n* = 10); arrows indicate days of i.p. injection of DT. Data are pooled from two (*Mpo^−/−^* PMNs → *PMN^DTR^* group), three (*PMN^DTR^* group), or five (*PMN^WT^* and WT PMNs → *PMN^DTR^* groups) independent experiments. \*\*\*, P \< 0.001 versus *PMN^WT^* group and ^\#^, P \< 0.05; ^\#\#^, P \< 0.01 versus WT PMNs → *PMN^DTR^* group by Mantel--Cox log-rank test.](JEM_20161238_Fig3){#fig3}

Although several myeloid cell types can produce MPO, including neutrophils, monocytes, and macrophages, we found that MPO levels in the peritoneal cavity were reduced by 70% in neutrophil-depleted *PMN^DTR^* mice compared with *PMN^WT^* mice 6 h after LPS injection ([Fig. 3 E](#fig3){ref-type="fig"}). Using ex vivo bioluminescent imaging of MPO activity after Luminol administration ([@bib12]; Zhang et al., 2013), we found that MPO activity was increased in the spleen and liver of both WT and *PMN^WT^* mice after LPS, compared with PBS-treated controls ([Fig. 3, F, G, and I](#fig3){ref-type="fig"}). The pronounced MPO activity detected in the lungs was comparable between PBS- and LPS-treated mice ([Fig. 3, H and I](#fig3){ref-type="fig"}). MPO activity was markedly reduced in both *Mpo^−/−^* and *PMN^DTR^* mice in all of the organs we examined and was statistically indistinguishable between MPO-deficient and neutrophil-deficient animals ([Fig. 3, F--I](#fig3){ref-type="fig"}; and Fig. S3 I), suggesting that neutrophils are the major source of MPO after LPS injection in vivo.

Finally, we performed adoptive transfer experiments to assess directly the importance of neutrophil-derived MPO during LPS endotoxemia. As a control, we first tested the efficiency of neutrophil engraftment in neutrophil-depleted *PMN^DTR^* mice or *PMN^WT^* controls using purified YFP^+^ neutrophils (isolated from the BM of MRP8-Cre^+^; ROSA-iEYFP^KI^ mice). We found significantly more circulating YFP^+^ neutrophils in the blood of *PMN^DTR^* mice compared with *PMN^WT^* mice 4 h after engraftment, indicating that *PMN^DTR^* mice (in which endogenous neutrophils are depleted) represent an attractive model for adoptive transfer experiments (Fig. S3, J--L). We then engrafted *PMN^DTR^* mice with neutrophils purified from either WT mice (WT PMNs → *PMN^DTR^*) or *Mpo^−/−^* mice (*Mpo^−/−^* PMNs → *PMN^DTR^*). LPS-induced hypothermia and survival in WT PMNs → *PMN^DTR^* mice were similar to those observed in neutrophil-sufficient *PMN^WT^* mice ([Fig. 3, J and K](#fig3){ref-type="fig"}). In contrast, *Mpo^−/−^* PMNs → *PMN^DTR^* mice experienced significantly greater hypothermia and mortality compared with either WT PMNs → *PMN^DTR^* mice or *PMN^WT^* mice, and the responses in *Mpo^−/−^* PMNs → *PMN^DTR^* mice were statistically indistinguishable from those of *PMN^DTR^* mice not engrafted with neutrophils ([Fig. 3, J and K](#fig3){ref-type="fig"}). Thus, the adoptive transfer of MPO-sufficient, but not MPO-deficient, neutrophils ameliorated LPS-induced hypothermia and enhanced survival of neutrophil-depleted mice. Collectively, our data indicate that the protective function of neutrophils during endotoxemia is dependent, at least in part, on their major enzyme MPO.

Given the short half-life of adoptively transferred neutrophils, it is likely that the protective function of neutrophils and MPO in this endotoxemia model occurs early after exposure to LPS. In agreement with this, we observed markedly enhanced hypothermia in neutrophil-depleted mice and MPO-deficient mice compared with their respective controls as early as 3--6 h after injection of LPS ([Fig. 1, D and F](#fig1){ref-type="fig"}; and [Fig. 3 B](#fig3){ref-type="fig"}). In addition, mortality rates were already much higher at 15 h in both neutrophil-depleted and MPO-deficient mice compared with controls ([Fig. 1, E and G](#fig1){ref-type="fig"}; and [Fig. 3 C](#fig3){ref-type="fig"}).

The mechanisms by which neutrophil-derived MPO is protective during endotoxemia may be intrinsically MPO-dependent and/or secondary to phenotypic or functional alterations in neutrophils. MPO has been reported to bind to and activate neutrophils, support cell adhesion, and prolong neutrophil survival, mainly via interactions with CD11b/CD18 integrins ([@bib16]; [@bib23]; [@bib8]) or by electrostatic interactions ([@bib20]). Through such effects, MPO may support appropriate neutrophil localization in response to changes induced by systemic endotoxin and therefore help to localize neutrophil regulatory functions. Neutrophil death is also thought to contribute importantly to the control and resolution of inflammation, and macrophage uptake of aging or apoptotic neutrophils can dampen the inflammatory responses of the macrophages themselves ([@bib10]; [@bib33]). Indeed, the intraperitoneal injection of apoptotic neutrophils was found to protect mice during LPS-induced endotoxic shock via CD14-dependent macrophage uptake ([@bib34]). In our hands, the transfer of *Mpo^−/−^* neutrophils did not restore survival during endotoxemia, which suggests that the protective effect of neutrophil transfer is not merely attributable to the transfer of cells that thereafter undergo apoptosis. Conversely, it is possible that, in the absence of MPO, alterations in neutrophil apoptosis might impair subsequent macrophage reprogramming and the induction of pro-resolution pathways.

In addition, it was recently reported that MPO can limit collateral tissue damage during antimicrobial oxidative bursts by converting diffusible and relatively long-lived H~2~O~2~ into highly reactive but locally confined HOCl ([@bib35]). MPO-deficient mice exhibited increased H~2~O~2~ tissue levels during *Salmonella* infection, as well as increased lipid peroxidation and DNA damage. Although those authors described a local phenomenon occurring at the pathogen surface and in the surrounding tissues, it is possible that such anomalous reactive oxygen species generation and compartmentalization can also contribute, at least in part, to the exacerbated systemic inflammation that we observed in neutrophil- or MPO-deficient mice after LPS challenge. Intriguingly, MPO also can have antiinflammatory effects directly by its catalytic action, via the oxidative modification or destruction of soluble mediators of inflammation. Notable candidates include high-mobility group protein 1 (HMGB1), associated with lethality after endotoxin exposure ([@bib38]) because the oxidative modification of HMGB1 determines its inflammatory effects ([@bib37]; [@bib41]). MPO can catalyze the oxidation of lipid mediators, such as leukotrienes and prostaglandins ([@bib43]), and lipid peroxidation is a feature of systemic inflammation ([@bib40]). Indeed, after endotoxin challenge, *Mpo^−/−^* mice were found to have elevated plasma levels of cysteinyl leukotrienes and reduced oxidative metabolites of arachidonic acid and linoleic acid ([@bib22]). Thus, MPO has the potential to systemically regulate the acute inflammatory response by modulating the formation of pro- and antiinflammatory lipid mediators.

Endotoxin challenge is a model of systemic inflammation relevant to our understanding of inflammatory pathways in multiple disease states: critically ill, post-trauma, or septic patients are characterized by severe systemic inflammation. Moreover, immune suppression is a secondary component of these conditions and is associated with poor patient outcome ([@bib15]); "defective" neutrophil function is observed in such settings, although the heterogeneity of neutrophil subsets is rarely addressed ([@bib31]). Importantly, LPS exposure mimics the systemic immune activation that occurs during infection, yet decoupled from the presence of a pathogen. Here, we have identified an unexpected new role for neutrophils and neutrophil-derived MPO: enhancing innate host resistance to the toxic effects of LPS. Our results imply that, in addition to their direct antimicrobial functions, neutrophils and MPO can contribute to optimal host protection by modulating inflammation and limiting the toxic effects of endotoxins.

Materials and methods {#s06}
=====================

Mice {#s07}
----

C57BL/6J SPF (WT) mice were bred at the Stanford University Research Animal Facility or purchased from The Jackson Laboratory or Charles River and used for experiments after maintaining the mice for at least 1 wk in SPF conditions in either animal facility (Stanford or Pasteur). C57BL/6J GF mice were obtained from the Unit of Transgenesis, Archiving and Animal Models TAAM, UPS44, Orleans, France, or from Institut Pasteur and were maintained in sterile isolators at Institut Pasteur. ROSA-iDTR^KI^ mice (C57BL/6-*Gt(ROSA)26Sor^tm1(HBEGF)Awai^*/J) were purchased from The Jackson Laboratory. *MRP8-Cre^+^* mice (B6.Cg-*Tg(S100A8-cre,-EGFP)1Ilw/J*) were obtained from I. Weissman (Stanford University, Stanford, CA) and C. Lowell (University of California San Francisco, San Francisco, CA). *MRP8-Cre^+^* mice were crossed with ROSA-iDTR^KI^ mice to generate *PMN^DTR^* mice (MRP8-Cre^+^; ROSA-iDTR^KI^) and *PMN^WT^* littermate controls (MRP8-Cre^−^; ROSA-iDTR^KI^). ROSA-iEYFP^KI^ reporter mice (B6.129X1-*Gt(ROSA)26Sor^tm1(EYFP)Cos^*/J) were obtained from G. Eberl (Institut Pasteur, Paris, France) and crossed with *MRP8-Cre^+^* mice to generate MRP8-Cre^+^; iEYFP^KI^ mice with YFP-fluorescent neutrophils (Figs. S2 B and S3, J--L). *Mpo^−/−^* mice (B6.129X1-Mpotm1Lus/J) were purchased from The Jackson Laboratory and bred in the Institut Pasteur or Stanford University SPF Animal Facilities. We used age- and sex-matched mice for all experiments. All animal care and experimentation were conducted in compliance with the guidelines of the National Institutes of Health and with the specific approval of the Institutional Animal Care and Use Committees of Stanford University and the Animal Ethics committee (Institut Pasteur, Paris, France) registered under \#C2EA-89.

DT- and antibody-mediated ablation of neutrophils {#s08}
-------------------------------------------------

*PMN^DTR^* mice and *PMN^WT^* littermate control mice were injected i.p. with 500 ng DT (Sigma-Aldrich). For antibody-mediated neutrophil depletion, WT mice were injected i.p. with anti-Ly6G (clone 1A8, 500 µg), anti-Gr-1 (clone RB6-8C5, 300 µg) or respective isotype control antibodies (rat IgG2a clone 2A3 or rat IgG2b clone LTF-2). Injections were performed in 200 µl PBS commencing 1 d before challenge; additional injections were performed 2 h before LPS injection or CLP and daily thereafter. The RB6-8C5 antibodies used at the Institut Pasteur ([Fig. 1, H and I](#fig1){ref-type="fig"}) were produced from hybridomas provided by R. Coffman (Dynavax Technologies, Berkeley, CA), and purified by Protein G affinity purification from hybridoma supernatants. All other antibodies were from Bio X Cell.

In vivo treatments {#s09}
------------------

Mice were injected i.p. with LPS at 15 mg/kg (for the experiments performed at Institut Pasteur; [Fig. 1, H and I](#fig1){ref-type="fig"}), 25 mg/kg, or the indicated doses in 200 µl PBS ([Fig. 1, A--C](#fig1){ref-type="fig"}; and Fig. S1, A--D; *Escherichia coli*, serotype 055:B5; Sigma-Aldrich). Hypothermia was monitored, and mice were observed for mortality at least twice daily. Mice that were clearly moribund were euthanized. For experiments involving GF mice, treatments were performed in parallel between GF and SPF facilities at Institut Pasteur, and all solutions were prepared sterile. For pharmacological inhibition of MPO activity, mice were injected i.p. with 80 mg/kg MPO inhibitor 4-ABAH (Sigma-Aldrich; Zhang et al., 2013) 3 h before and 6, 24, and 36 h after challenge with LPS ([Fig. 3 D](#fig3){ref-type="fig"}).

Flow cytometry and blood cell analyses {#s10}
--------------------------------------

We used flow cytometry to identify and enumerate immune cells in BM, peripheral blood, peritoneal lavage fluid, and spleen. In brief, red blood cells were lysed by treatment with pH 7.3 ACK lysis buffer (0.15 M NH~4~Cl, 1 mM KHCO~3~, and 0.1 mM EDTA, pH 8.0) or RBC lysis buffer (BD). Peritoneal lavages were performed with 2 ml of ice-cold PBS, and cells were washed and counted using a hemocytometer. In some experiments, cells were blocked with unconjugated anti-FcγRII/III (CD16/CD32) antibodies (Bio X Cell) on ice for 5 min. Cells were stained with a combination of antibodies on ice for 30 min. Immune cell populations were identified as follows: neutrophils (CD11b^+^/Gr-1^high^, CD11b^+^/Ly6G^+^, or CD45^+^/CD11b^+^/Ly6G^+^), blood monocytes (CD11b^+^/Ly6G^−^/CD115^+^ and Ly6C^hi^ or Ly6C^low^), spleen macrophages (CD11b^low/+^/F4/80^+^), spleen monocytes (CD11b^+^/F4/80^low/−^/Ly6G^−^/SSC^low^ and Ly6C^hi^ or Ly6C^int^) and monocyte-derived DCs (CD11b^+^/F4/80^low/−^/Ly6G^−^/SSC^low^/Ly6C^low^/CD11c^+^), macrophages in peritoneal lavage fluid (CD11b^+^/F4/80^+^), basophils (CD49b^+^/FcεRIα^+^), mast cells (c-KIT^+^/FcεRIα^+^), eosinophils (CD11b^+^; Siglec-F^+^; SSC^high^), dendritic cells (CD11c^+^), T cells (CD3ε^+^/B220^−^), and B cells (CD3ε^−^/B220^+^). For analysis of BM progenitor cells (Fig. S1), BM cells were stained with lineage markers (Gr-1, Ter119, CD4, CD8, CD3, B220, CD19), Sca-1, c-KIT, CD34, and FcγRII/III (CD16/32). BM progenitor cell populations were identified as follows: GMPs (Lineage^−^/c-KIT^+^/Sca-1^−^/CD34^+^/FcγRII/III^high^), common myeloid progenitors (Lineage^−^/c-KIT^+^/Sca-1^−^/CD34^+^/FcγRII/III^int^), and megakaryocyte-erythrocyte progenitors (Lineage^−^/c-KIT^+^/Sca-1^−^/CD34^−^/FcγRII/III^−^). Antibodies used were Gr-1 (RB6-8C5), Ly6C (AL21), Ly6G (1A8), CD11b (M1/70), F4/80 (BM8), FcεRIα (MAR-1), c-KIT (2B8), CD49b (DX5), Siglec-F (E50-2440), CD11c (N418), CD3ε (145-2C11), CD4 (RM4-5), CD8 (53--6.7), CD19 (6D5), CD34 (RAM34), CD45 (30F11), Sca-1 (D7), B220 (RA3-6B2), or CD62L (MEL-14). All antibodies were purchased from eBioscience, BD, Miltenyi Biotec, or BioLegend. Data were acquired using FACSCalibur, LSRII, Accuri C6 (all from BD), or MACSQuant (Miltenyi Biotec) flow cytometers. FITC channel was used for analysis of GFP or YFP expression ([Fig. 2 A](#fig2){ref-type="fig"} and Figs. S2 and S3). Data were analyzed with FlowJo software (Tree Star). Dead cells (identified by staining with propidium iodide or LIVE/DEAD Fixable Dead Cell Stains; Invitrogen) were not included in the analysis. For complete blood analysis (Fig. S2), total red blood cells, white blood cells, and platelets were counted using the Abbott Cell-Dyn 3500 automated hematology analyzer.

CLP {#s11}
---

CLP was performed as described previously ([@bib30]). In brief, mice were deeply anesthetized by intramuscular injection of 100 mg/kg ketamine and 20 mg/kg xylazine, the cecum was exposed by a 1- to 2-cm midline incision on the anterior abdomen, and ligation of the distal half of the cecum and single puncture (with a 22-gauge needle) of the ligated segment were performed. The cecum was then placed back into the abdomen, 1 ml of sterile saline (pyrogen-free 0.9% NaCl) was administered into the peritoneal cavity, and the incision was closed using 9-mm steel wound clips. Mice were observed for mortality at least four times daily. Mice that were clearly moribund were euthanized by CO~2~ inhalation.

Quantification of bacterial CFUs {#s12}
--------------------------------

Dilutions of peritoneal lavage fluids or blood were prepared, and samples were plated on lysogeny broth agar for peritoneal fluids or tryptose blood agar (BD), respectively. Colonies were counted after overnight incubation at 37°C.

Quantification of cytokines and chemokines in plasma {#s13}
----------------------------------------------------

Levels of selected cytokines and chemokines in mouse plasma were analyzed by Cytometric Bead Array (mouse inflammation CBA kit; BD) and quantified using an Accuri C6 flow cytometer (BD).

Measurements of MPO and MPO activity {#s14}
------------------------------------

MPO was quantified from peritoneal lavage fluid by ELISA according to the manufacturer's instructions (R&D Systems). Bioluminescent imaging of MPO activity was performed 6 h after LPS injection (Zhang et al., 2013). Mice were anesthetized (isoflurane inhalation), and 10 min after injection of luminol-R (a mixture of Luminol \[200 mg/kg; Sigma-Aldrich\] and near-infrared quantum dots \[QD800 from Life Sciences; 100 pmol\]; 100 µl each i.p. + i.v.), animals were sacrificed and organs were sampled for imaging (2 min; open filter). Imaging and analysis was performed using an IVIS Spectrum with LivingImage software (Xenogen Product from PerkinElmer). We controlled for the in vivo distribution of luminol-R by fluorescent imaging of QD800 particles (excitation 745 nm, emission 800 nm) and found no difference in fluorescence intensity between organs from LPS-treated neutrophil-sufficient and neutrophil-depleted mice or LPS-treated WT and *Mpo^−/−^* mice.

Adoptive transfer of neutrophils {#s15}
--------------------------------

BM neutrophils were purified from the tibia and femur by negative selection using the EasySep Mouse Neutrophil Enrichment kit (STEMCELL Technologies; \>90% Gr-1^+^ CD11b^+^ and Ly-6G^+^ CD11b^+^ on average). Neutrophils (10^7^ cells in [Fig. 3 \[J and K\]](#fig3){ref-type="fig"} and 2--10 × 10^6^ in Fig. S3 \[J--L\]) were transferred i.v. (20--30 min before LPS injection; [Fig. 3, J and K](#fig3){ref-type="fig"}).

Statistical analyses {#s16}
--------------------

Data are presented as mean ± SEM. Data were analyzed for statistical significance using Mantel--Cox log-rank test, unpaired Mann--Whitney *U* test, or unpaired Student's *t* test, as indicated in figure legends. P-values \<0.05 are considered statistically significant.

Online supplemental material {#s17}
----------------------------

Fig. S1 contains data pertaining to the phenotype of neutrophils after LPS treatment and the effect of neutrophil depletion in endotoxemia induced by low-dose LPS or LPS/[d]{.smallcaps}-galactosamine. Fig. S2 shows the analysis of GFP expression in MRP8-Cre/IRES-GFP mice, the effect of DT treatment on other cell populations in *PMN^DTR^* mice, and the responses of DT-treated *PMN^DTR^* mice in the CLP model of sepsis. Fig. S3 shows the responses of MPO-deficient mice in the CLP model of sepsis and LPS-induced endotoxemia, the systemic quantification of MPO-induced bioluminescence, and the levels of neutrophils after adoptive transfer in *PMN^WT^* versus *PMN^DTR^* mice.

Supplementary Material
======================

###### Supplemental Materials (PDF)
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